

This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

5'-O-Ester Prodrugs of Potent and Selective Anti-HIV Agent—2',3'-Dideoxy-3'-fluoro-2-thiothymidine (S²FLT): Synthesis and Anti-HIV Activity

A. Miazga^{ab}; N. E. Poopeiko^a; A. Piasek^c; M. A. Siweckar^a; T. Kulikowski^a

^a Institute of Biochemistry and Biophysics, Warszawa, Poland ^b Polish Academy of Sciences, Institute of Biochemistry and Biophysics, Warszawa, Poland ^c Polish Academy of Sciences, Institute of Experimental Medicine, Warszawa, Poland

Online publication date: 09 August 2003

To cite this Article Miazga, A. , Poopeiko, N. E. , Piasek, A. , Siweckar, M. A. and Kulikowski, T.(2003) '5'-O-Ester Prodrugs of Potent and Selective Anti-HIV Agent—2',3'-Dideoxy-3'-fluoro-2-thiothymidine (S²FLT): Synthesis and Anti-HIV Activity', Nucleosides, Nucleotides and Nucleic Acids, 22: 5, 805 — 807

To link to this Article: DOI: 10.1081/NCN-120022639

URL: <http://dx.doi.org/10.1081/NCN-120022639>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

5'-O-Ester Prodrugs of Potent and Selective Anti-HIV Agent—2',3'-Dideoxy-3'-fluoro-2-thiothymidine (S²FLT): Synthesis and Anti-HIV Activity

A. Miazga,^{1,*} N. E. Poopeiko,^{1,#} A. Piasek,² M. A. Siweckar,¹
and T. Kulikowski¹

¹Institute of Biochemistry and Biophysics and

²Institute of Experimental Medicine, Polish Academy of Sciences,
Warszawa, Poland

ABSTRACT

Novel synthesis of 2',3'-dideoxy-3'-fluoro-2-thiothymidine (SFLT) based on transformation of appropriately protected 1-β-D-*threo*-ribofuranosylthymine is presented. The synthesis and evaluation of SFLT 5'-O-ester prodrugs enzymatic hydrolysis, as well as their anti-HIV activity, is also described.

Key Words: S²FLT; SFLT prodrugs; HIV-1 inhibitors.

INTRODUCTION

2',3'-Dideoxy-3'-fluoro-2-thiothymidine (S²FLT) is a potent and selective inhibitor of HIV^[1] and its reverse transcriptase,^[2] however its activity is lower than that of

*Correspondence: A. Miazga, Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 5A Pawinskiego St., 02-106 Warszawa, Poland; Fax: +48 22 391 21623; E-mail: jagoda@poczta.ibb.waw.pl.


#On leave of absence from the Institute of Bioorganic Chemistry, Belorussian Academy of Sciences, Minsk, Belorussia.



2',3'-dideoxy-3'-fluoro-thymidine (FLT) which is the most potent anti-HIV agent, but with pronounced in vivo hematological toxicity. On the other hand it was previously shown that such FLT derivatives as 5'-O-myristic acid analogues exhibit enhanced anti-HIV activity, increased lipophilic properties and better selectivity index.^[3] In addition such derivatives may act as bifunctional inhibitors of two important enzymes: HIV reverse transcriptase and myristoyl-CoA:protein N-myristoyl-transferase (E.C. 2.3.1.97). To increase the antiviral activity and to improve selectivity we decided to synthesize 5'-O-ester prodrugs of S²FLT.

SYNTHESIS

A new procedure, based on transformation of the known compound 1-(3-O-methanesulphonyl-5-O-trityl-2-deoxy-β-D-*threo*-ribofuranosyl)thymine in four steps, was applied to the synthesis of S²FLT. Ethoxylation of position 2 of thymine ring of 1-(3-O-methanesulphonyl-5-O-trityl-2-deoxy-β-D-*threo*-ribofuranosyl)thymine with simultaneous inversion of *erythro*-3'-hydroxyl to *threo* configuration lead to 1-(5-O-trityl-2-deoxy-β-D-*threo*-pentofuranosyl)-2-O-ethylthymine.^[4] The latter compound was easily transformed into 1-(5-O-trityl-2-deoxy-β-D-*threo*-pentofuranosyl)-2-thiothymine with the use of hydrogen sulfide in the presence of tetramethylguanidine. Fluorination of the 2-thio derivative with DAST gave 1-(5-O-trityl-2,3-dideoxy-3-fluoro-β-D-*erythro*-pentofuranosyl)-2-thiothymine. Deprotection of the tritylated compound with the use of 80% AcOH led to S²FLT with spectral properties identical with those previously described.^[1]



Scheme 1. Preparation of 5'-O-myristoilated analogues of S²FLT.

S²FLT was then esterified on its 5'-hydroxyl group using a variety of myristic acid analogues in the presence of oxalyl chloride and DMAP to afford the corresponding esters **1-6** (Sch. 1).

BIOLOGICAL RESULTS

Preliminary tests of antiviral activity in vitro were carried out using the syncytia-inducing laboratory HIV-1 (cat#3) strain and MT-2 cells. Preliminary investigation

Table 1. Half-life for in vitro enzymatic hydrolysis of 5'-O-myristoyl derivatives of S²FLT.

Compound	Porcine liver esterase, t _{1/2} (min)
1	25
2	2
3	10
4	10
5	10
6	> 60

of antiviral properties of the compounds **1–6** shows that 5'-O-myristoylated S²FLT derivatives **2** and **3** are the most potent inhibitors of HIV-1 and exhibit ca. ten times higher anti-HIV-1 activity and higher therapeutic index than their mother nucleoside S²FLT.

All derivatives are good substrates for porcine liver esterase with enzymatic hydrolysis half-life (t_{1/2}) 2–25 min (Table 1).

ACKNOWLEDGMENT

This work was supported by the Polish State Committee for Scientific Research, grant No. 4P05F03318p01.

REFERENCES

1. Poopeiko, N.E.; Poznanski, J.; Drabikowska, A.; Balzarini, J.; De Clercq, E.; Mikhailopulo, I.A.; Shugar, D.; Kulikowski, T. Synthesis, solution conformation and biological properties of 2',3'-dideoxy-3'-fluoro-D-*erythro*-pentofuranosides of 2-thiouracil and 2-thiothymine. *Nucleosides Nucleotides* **1995**, *14*, 435–437.
2. Miazga, A.; Felczak, K.; Bretner, M.; Siwecka, M.A.; Piasek, A.; Kulikowski, T. Thiated derivatives of 2',3'-dideoxy-3'-fluorothymidine and their phosphorylated and phosphonylated derivatives: synthesis interaction with HIV reverse transcriptase and in vitro anti-HIV activity. In Abstracts of XV International Round Table Nucleosides, Nucleotides and Nucleic Acids, Leuven, Belgium, Sept 10–14, 2002.
3. Parang, K.; Knauss, E.E.; Wiebe, L.L. Synthesis, in vitro anti-HIV activity, and biological, stability of 5'-O-myristoyl analogue derivatives of 3'-fluoro-2',3'-dideoxythymidine (FLT) as potential bifunctional prodrugs of FLT. *Nucleosides Nucleotides* **1998**, *17*, 987–1008.
4. Joshi, B.V.; Reese, C.B.; Varaprasad, C.V.N.S. Synthesis of pyrimidine 2',3'-dideoxy-2-thio-nucleosides. *Nucleosides Nucleotides* **1995**, *14*, 209–218.



